Fintel reports that on December 19, 2025, Goldman Sachs upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from Neutral to Buy.
Analyst Price Forecast Suggests 29.38% Upside
As of December 6, 2025, the average one-year price target for Cytokinetics is $81.15/share. The forecasts range from a low of $55.55 to a high of $126.00. The average price target represents an increase of 29.38% from its latest reported closing price of $62.72 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cytokinetics is 354MM, an increase of 305.84%. The projected annual non-GAAP EPS is -3.99.
What is the Fund Sentiment?
There are 810 funds or institutions reporting positions in Cytokinetics. This is an increase of 40 owner(s) or 5.19% in the last quarter. Average portfolio weight of all funds dedicated to CYTK is 0.25%, an increase of 13.92%. Total shares owned by institutions increased in the last three months by 0.77% to 165,475K shares. 
The put/call ratio of CYTK is 0.21, indicating a bullish outlook.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 19,080K shares representing 15.61% ownership of the company. In its prior filing, the firm reported owning 17,602K shares , representing an increase of 7.75%. The firm increased its portfolio allocation in CYTK by 74.55% over the last quarter.
Wellington Management Group Llp holds 7,409K shares representing 6.06% ownership of the company. In its prior filing, the firm reported owning 7,828K shares , representing a decrease of 5.66%. The firm decreased its portfolio allocation in CYTK by 78.51% over the last quarter.
Deep Track Capital holds 4,300K shares representing 3.52% ownership of the company. In its prior filing, the firm reported owning 3,650K shares , representing an increase of 15.12%. The firm increased its portfolio allocation in CYTK by 70.53% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 4,068K shares representing 3.33% ownership of the company. No change in the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 3,890K shares representing 3.18% ownership of the company. In its prior filing, the firm reported owning 3,848K shares , representing an increase of 1.08%. The firm decreased its portfolio allocation in CYTK by 21.65% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
